Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) EPS (Weighted Average and Diluted) (2019 - 2025)

Sutro Biopharma's EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at -$0.67 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 24.72% year-over-year to -$0.67; the TTM value through Sep 2025 reached -$2.6, down 67.74%, while the annual FY2024 figure was -$2.96, 66.29% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.67 at Sutro Biopharma, down from -$0.13 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.52 in Q4 2023 and bottomed at -$0.91 in Q1 2025.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.66 (2021), against an average of -$0.58.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 311.32% in 2022 before it soared 185.25% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.83 in 2021, then grew by 26.51% to -$0.61 in 2022, then skyrocketed by 185.25% to $0.52 in 2023, then crashed by 271.15% to -$0.89 in 2024, then increased by 24.72% to -$0.67 in 2025.
  • Per Business Quant, the three most recent readings for STRO's EPS (Weighted Average and Diluted) are -$0.67 (Q3 2025), -$0.13 (Q2 2025), and -$0.91 (Q1 2025).